University of Colorado Cancer Center study shows "extremely promising” early phase 1 clinical trial results for the investigational drug AG-120 against the subset of patients with acute myeloid leukemia (AML) harboring mutations in the gene IDH.
Life's extremists, a family of microbes called Archaea, may be an untapped source of new antibacterial drugs. That conclusion arises from the discovery of the first antibacterial gene in this ancient lineage.
Researchers are developing a novel prochlorperazine nasal spray formulation as a potential new treatment for migraines.
A nasal vaccine in development by researchers at The University of Texas at Austin has been shown to provide long-term protection for non-human primates against the deadly Ebola virus.
Women who take a common type of medication to control their blood pressure are not at increased risk of developing breast cancer due to the drug, according to new study by researchers at the Intermountain Medical Center Heart Institute in Murray, Utah.
The investigational drug Losartan, which worked better in an animal model, was equally effective to a high dose of the beta blocker, atenolol in treating Marfan syndrome, a rare genetic disease.
A new study has identified an FDA approved cancer drug, crizotinib, as a possible new coating for drug-eluting stents. Researchers found that crizotinib in mice helped prevent the narrowing of blood vessels after stenting without affecting the blood vessel lining. Results of this study were published today in The Journal of Clinical Investigation.
An antibody therapy already in clinical trials to treat chronic lymphocytic leukemia may also prove effective against ovarian cancer – and likely other cancers as well, report researchers at the University of California, San Diego School of Medicine.
Researchers at University of California, San Diego School of Medicine have developed a way to chemically disguise RNAi drugs so that they are able to enter cells. Once inside, cellular machinery converts these disguised drug precursors — called siRNNs — into active RNAi drugs.
Brief usage of the painkiller oxycodone may impair behavioral flexibility even after that use ends, suggesting impaired decision-making as an enduring consequence of exposure, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published November 17 in the journal Learning and Memory.
Patients with rheumatic diseases who are treated with denosumab (Prolia®, Xgeva®) either alone, or in combination with either biologic or non-biologic disease-modifying antirheumatic drugs (DMARDs), do not appear to have a significant increased risk of infections.
Keryx Biopharmaceuticals, Inc. today announced results from a 48-week Open Label Extension (OLE) safety study in which Ferric Citrate demonstrated long-term safety and efficacy in dialysis-dependent chronic kidney disease (CKD) patients with elevated serum phosphorus levels, or hyperphosphatemia. The OLE findings were presented as a late-breaking poster (Abstract #SA-PO1102) at the 2014 American Society of Nephrology’s (ASN) Kidney Week meeting in Philadelphia, PA.
A new perspective piece in The New England Journal of Medicine, written by health policy researchers at the University of Pennsylvania’s Perelman School of Medicine and Leonard Davis Institute of Health Economics, describes various digital marketing tactics targeting physicians, outlines concerns about their influence over physician decisions, and makes recommendations about how to adapt policies to keep up with the changing nature of pharmaceutical marketing.
A parallel between the dilemmas facing medicine in the nineteenth century and those that currently exist in the field of mental health could explain why psychotropic drugs are increasingly prescribed.
A University of Colorado Cancer Center study published online this week in the journal Molecular Cancer Therapeutics reports anti-cancer activity in 10 out of 11 patient tumor samples grown in mice and treated with the experimental drug TAK-733, a small molecule inhibitor of MEK1/2.
A controversial medication used by breastfeeding women should not be restricted because of the benefits it offers mothers and their babies, according to researchers at the University of Adelaide.
Chemists at The Scripps Research Institute (TSRI) and the Shanghai Institute of Organic Chemistry have described a method for creating and modifying organic compounds that overcomes a major limitation of previous methods.
Study shows that one way to solve problems of synthesis of natural compounds is to figure out how an organism solves the problem itself, and then modify it for a particular use.
Interim data from an ongoing Phase I/II trial of Actimab-A, an innovative targeted payload immunotherapy, demonstrated a number of positive findings, including extension of overall survival and significant reductions in bone marrow blasts in older patients with newly diagnosed Acute Myeloid Leukemia (AML).
Basic research in 2002 and years of follow-up studies led UAB’s Anath Shalev, M.D., to a human trial of a diabetes drug unlike any in use.
Commonly prescribed, older drugs for arthritis and pain may increase the risk of death from stroke, according to a study published in the November 5, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology.
A recently awarded grant will fund a human clinical trial in type 1 diabetes beginning in early 2015 to see if verapamil will have an effect in humans by attacking the disease where it occurs. Meanwhile, more small molecule drugs at UAB are in development.
A common drug used to clean a person’s bowels before a colonoscopy could become the future standard of care for patients with acute hepatic encephalopathy (HE), a mental disorientation problem that affects up to one in two cirrhosis patients. The finding comes from new research, known as the “HELP Clinical Trial,” that appeared in JAMA Internal Medicine on Sept. 22.
A study presented at the annual meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) adds more credence to a growing awareness of the high prevalence of vitamin D deficiency in neuromuscular disease.
Although oral hormonal therapy is known to substantially reduce breast cancer recurrence in women with hormone receptor–positive tumors, about one-half of patients fail to take their medications as directed. A new study by Columbia University Medical Center (CUMC) researchers has found that the introduction of generic aromatase inhibitors (the most common type of hormone therapy), which are considerably less expensive than their brand name counterparts, increased treatment adherence by 50 percent.
In less than a minute, a miniature device developed at the University of Montreal can measure a patient's blood for methotrexate, a commonly used but potentially toxic cancer drug. Just as accurate and ten times less expensive than equipment currently used in hospitals, this nanoscale device has an optical system that can rapidly gauge the optimal dose of methotrexate a patient needs, while minimizing the drug's adverse effects.
Scientists will receive about $1.25 million from the Center for the Advancement of Science in Space to develop an implantable device that delivers therapeutic drugs at a rate guided by remote control. The device's effectiveness will be tested aboard the International Space Station and on Earth's surface.
Ewing sarcoma tumors disappeared and did not return in more than 70 percent of mice treated with combination therapy that included drugs from a family of experimental agents developed to fight breast cancer, reported St. Jude Children’s Research Hospital scientists.
This year the College offers a series of pre-recorded virtual press briefings which feature the insights of leading gastroenterology experts on several key abstracts that will be unveiled at ACG 2014 in the areas related to hepatitis C
This year the College offers a series of pre-recorded virtual press briefings which feature the insights of leading gastroenterology experts on several key abstracts that will be unveiled at ACG 2014 in the areas related to drug induced liver injury.
A paper being published today outlines developments in a system launched last year to allow pharmaceutical firms to share their clinical trials data for new drugs with outside investigators. Brian Strom, a co-author and the chair of the system's advisory committee, discusses data sharing's potential impact.
Biomedical engineering researchers have developed a drug delivery system consisting of nanoscale “cocoons” made of DNA that target cancer cells and trick the cells into absorbing the cocoon before unleashing anticancer drugs.
Using X-rays and neutron beams, a team of researchers have revealed the inner workings of a master switch that regulates basic cellular functions, but that also, when mutated, contributes to cancer, cardiovascular disease and other deadly disorders.
PKA protein helps regulate cellular functions, but also causes disease when it mutates.
Pharmaceutical companies have largely abandoned the business of discovering and developing antibiotics and our stock of these “miracle drugs” is beginning to shrink. Michael Kinch and his colleagues at Washington University in St. Louis are working to create new models for drug discovery that could replace the failed private enterprise model.
Pharmaceutical companies will collaborate with researchers at the University of California, San Diego to provide previously unreleased proprietary data for drug discovery through a new $3.7 million effort funded by the National Institutes for Health. The project, which is led by UC San Diego principal investigators Rommie Amaro, Victoria Feher and Dr. Michael K. Gilson, includes a major subcontract to Rutgers University, directed by Dr. Stephen K. Burley of the Research Collaboratory for Structural Bioinformatics Protein Data Bank.
A University of Nebraska Medical Center research team has determined that a longtime antibiotic, vancomycin, is still effective in treating Staphylococcus aureus bloodstream infections and that physicians should continue to use the drug even though several newer antibiotics are now available in the marketplace.
Each year, 36 million people with chronic congestion and runny noses seek treatment from their primary care physicians. Without a way for doctors to easily distinguish viral from bacterial infections, more than half of patients will end up getting antibiotics for an infection that they don’t actually have. The invention of a rapid, in-office test, based on bacterial biomarkers, could help physicians identify the infections that need antibiotics while helping reduce the growing problem of antibiotic resistance.
A new study from UCLA found that a drug being evaluated to treat an entirely different disorder helped slow the progression of Parkinson’s disease in mice.
Two studies published in the October 2014 issue of Health Affairs by a University of Chicago health economist examine spending on oral anti-cancer drugs as well as a federal program designed to help the poor, which researchers say instead helps hospitals boost profits.
Experiments in mice with a bone disorder similar to that in women after menopause show that a scientifically overlooked group of cells are likely crucial to the process of bone loss caused by the disorder. Their discovery not only raises the research profile of the cells, called preosteoclasts, but also explains the success and activity of an experimental osteoporosis drug with promising results in phase III clinical trials.
Cancer vaccines have recently emerged as a promising approach for killing tumor cells before they spread. But so far, most clinical candidates haven't worked that well. Now, scientists have developed a new way to deliver vaccines that successfully stifled tumor growth when tested in laboratory mice. And the key, they report in the journal ACS Nano, is in the vaccine's unique stealthy nanoparticles.
A formulation of the dye, rose bengal, which has been around for more than a century, has recently been shown to have promise in patients with cutaneous melanoma, one of the deadliest forms of the disease.
Medications are the leading cause of allergy-related sudden deaths in the U.S., according to an analysis of death certificates from 1999 to 2010, conducted by researchers at Montefiore Medical Center and Albert Einstein College of Medicine of Yeshiva University. The study, published online today in the Journal of Allergy and Clinical Immunology, also found that the risk of fatal drug-induced allergic reactions was particularly high among older people and African-Americans and that such deaths increased significantly in the U.S. in recent years.
University of Colorado Cancer Center researchers report 72 percent response rate with 19.2 month progression-free survival.
A University of Utah study shows for the first time that continuous infusion benzodiazepines – a class of sedatives that includes lorazepam and midazolam, once considered the standard of care in the ICU – are linked to an increased likelihood of death among patients who receive mechanical ventilation, when compared to the sedative propofol.
A federal, public database launched September 30 with the intention of bringing transparency to financial relationships between physicians and industry may instead result in opacity and misinterpretation, according to experts in bioethics, clinical care and public health at Johns Hopkins.
Every day, organ transplant patients around the world take a drug called rapamycin to keep their immune systems from rejecting their new kidneys and hearts. New research suggests that the same drug could help brain tumor patients by boosting the effect of new immune-based therapies.
A team led by the U.S. Department of Energy's Oak Ridge National Laboratory has unlocked the enzymatic synthesis process of rare sugars, which are useful in developing drugs with low side effects using a process more friendly to the environment.
Pharmacists have an important role in ensuring that clinical trials are conducted according to good clinical trials practices. The Hematology/Oncology Pharmacy Association has released the HOPA Investigational Drug Service Best Practice Standards, the first of its kind.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right